Proinflammatory cytokine secretion

Proinflammatory cytokine secretion refers to the **release of signaling proteins**—notably interleukins such as IL‑1β, IL‑6; tumor necrosis factor alpha (TNF‑α); interferon gamma (IFNγ); and others—from immune cells including macrophages, T helper cells, dendritic cells, and additional cell types in response to infection or injury. These molecules act as key regulators that initiate and amplify inflammation by recruiting immune cells to sites of tissue damage or pathogen invasion. The process is essential for mounting an effective innate immune response but can contribute to chronic inflammatory diseases if dysregulated. Excessive or persistent secretion is implicated in conditions such as autoimmune disorders, cardiovascular disease, cancer progression, neurodegenerative diseases, and more[2][3][7][8]. **Note:** "Proinflammatory cytokine secretion" describes a biological *process*, not a discrete molecular target like a receptor or enzyme. Therapeutic interventions generally focus on blocking individual proinflammatory cytokines or their receptors rather than inhibiting the entire secretory process[3][7]. Therefore this entry does **not correspond to a canonical druggable target**, but rather an important immunological mechanism underlying many therapeutic strategies.

Other names

Pro-inflammatory cytokine releaseInflammatory cytokine secretionSecretion of proinflammatory cytokines